AccuType® CP: Clopidogrel Response Testing
For some patients, the only indication of poor clopidogrel response to PLAVIX® (clopidogrel bisulfate) may be an atherothrombotic event, such as a heart attack or stroke. AccuType CP enables early identification of patients who are predisposed to poor therapy response.
PLAVIX is indicated for the reduction of atherothrombotic events for patients with a history of recent myocardial infarction, stroke, or established peripheral arterial disease, as well as patients who are to be managed with percutaneous coronary intervention.1 It is marketed in the U.S. under the trade name PLAVIX by Bristol-Myers Squibb and Sanofi-Aventis pharmaceuticals.2
PLAVIX and Genotyping: Statements from the FDA
- “Effectiveness of PLAVIX depends on activation to an active metabolite by the Cytochrome P450 (CYP) system, principally CYP2C19
- Poor metabolizers treated with PLAVIX at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function
- Tests are available to identify a patient’s CYP2C19 genotype and can be used as an aid in determining therapeutic strategy
- Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers”
How Clopidogrel Works
- Clopidogrel is a “pro-drug” that requires transformation in the liver into an active drug metabolite1
- This transformation is mediated by cytochrome P450 2C19 enzymes under control of the CYP2C19 gene
- “Active” clopidogrel metabolites inhibit platelet aggregation
AccuType CP can provide important information to help you determine if alternative medications should be prescribed for:
- Patients currently on clopidogrel where genotype is unknown
- Patients with a recent cardiac event despite treatment with clopidogrel
AccuType CP complements other clopidogrel testing methods that may require patients to be on the drug before you can determine the drug’s effectiveness.
|Distinct Advantages of AccuType CP Testing|
|These five |
(*2-*5 and *17)
|AccuType CP detects 99% of reduced function |
metabolizers in Asians and 90% in Caucasians
|AccuType CP provides you with relevant information to |
help you choose the right therapeutic course for your patients
|Our genetic counselors can provide additional assistance with AccuType CP results interpretation. Call 1-866-GENE-INFO (1-866-436-3463).|
- Bristol-Myers Squibb and Sanofi-Aventis. PLAVIX Web site. May 2010. Available at http://www.plavix.com/hcp/indications/index.aspx. Accessed September 1, 2010.
- Bristol-Myers Squibb and Sanofi-Aventis. PLAVIX Web site. May 2010. Available at http://www.plavix.com/Index.aspx. Accessed September 1, 2010.
- Food and Drug Administration press release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm204253.htm. Accessed September 1, 2010.
- Bristol-Myers Squibb and Sanofi-Aventis. PLAVIX Prescribing Information. Available at http://products.sanofi-aventis.us/PLAVIX/PLAVIX.html. Accessed September 1, 2010.
Ready to order?
See ordering and CPT codes, specimen requirements, test methodology, set-up schedule and moreVisit our Test Menu
Want more clinical information?
Visit our Test Selection and Interpretation Guide, for information relating to test selection, utilization, and interpretation.
Visit our Education Center for presentations, Expert Insights, and CEshttp://education.questdiagnostics.com/
Have questions? We’re here to help
Call or email us now.Get started with us